SCHEMBL5756790

SCHEMBL5756790

CCCNC(=O)c1ccc2[nH]c(-c3cc[nH]n3)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.46
ITK Q08881 3/20 0.44
KDM4E B2RXH2 7/20 0.42
GAA P10253 5/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 2/20 0.40
CYP17A1 P05093 1/20 0.39
CYP3A4 P08684 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
NAMPT P43490 1/20 0.38
ALOX15 P16050 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5753446 0.93 KDM4E (0.48) ITKKDM4EGAAALDH1A1HPGD
SCHEMBL5757315 0.91 ITK (0.53) RIPK1ITKKDM4EGAAALDH1A1
SCHEMBL5755542 0.91 RIPK1 (0.44) RIPK1ITKALDH1A1HDAC6CYP17A1
SCHEMBL5752904 0.90 ITK (0.55) ITKKDM4EGAAALDH1A1HPGD
SCHEMBL5755525 0.88 KDM4E (0.49) ITKKDM4EALDH1A1HPGDHDAC6
SCHEMBL5753964 0.87 KDM4E (0.46) ITKKDM4EALDH1A1HPGDHDAC6
SCHEMBL5755204 0.86 HPGD (0.53) ITKKDM4EALDH1A1HPGDL3MBTL1
SCHEMBL6478927 0.86 ITK (0.40) ITKKDM4EALDH1A1HPGDHDAC6
SCHEMBL6486561 0.85 ITK (0.41) ITKKDM4EGAAALDH1A1HDAC6
SCHEMBL5754329 0.85 KMT2A (0.45) ITKKDM4EGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648884-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2006-04-26 EP disclosed
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed
WO-2005005414-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 RIPK1 404/4885ITK 392/4885KDM4E 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.